

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東威高集團醫用高分子製品股份有限公司
Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

TRANSACTION PROGRESS UPDATE

The Transaction

The Board hereby announces that on 31 October 2025 (after trading hours), the Company, Weihai Shengxi, Weihai Ruiming, and Weigao Blood Purification entered into the conditional Sale and Purchase Agreement, pursuant to which Weigao Blood Purification will acquire 100% equity interest in WEGO Prefills, a non-wholly-owned subsidiary of the Company; and as the consideration, Weigao Blood Purification will issue a corresponding number of Consideration Shares to each of the WEGO Prefills Shareholders.

The Disposal

Pursuant to the Sale and Purchase Agreement, the Company and Weihai Ruiming, as Vendors, will sell a total of 95.9784% equity interest in WEGO Prefills to Weigao Blood Purification at an agreed price with reference to the appraisal value of the Subject Assets. The final consideration shall be determined by the parties by way of supplemental agreement upon the completion of the valuation of the Subject Assets.

* For identification purpose only

The Acquisition

Weigao Blood Purification will issue a corresponding number of Consideration Shares to each of the WEGO Prefills Shareholders at a price of RMB31.29 per Consideration Share. The number of Consideration Shares to be issued will be calculated by dividing the final consideration of the Disposal by the Issue Price per Consideration Share. The Consideration Shares to be issued to the Company and Weihai Ruiming will constitute a transaction in which the Company acquires the equity interest in Weigao Blood Purification.

As of the date of this announcement, the Company holds 23.53% equity interest in Weigao Blood Purification. Upon the completion of the Transaction, WEGO Prefills will become a wholly-owned subsidiary of Weigao Blood Purification, while Weigao Blood Purification may become a non-wholly-owned subsidiary of the Company. The accounts of WEGO Prefills, Weigao Blood Purification and their subsidiaries may be consolidated into the financial statements of the Company.

Implications under the Listing Rules

Based on the information available so far, the Company estimated that the respective highest applicable percentage ratios for the Disposal and the Acquisition may exceed 25% but below 75%/100% (as the case may be), and therefore may constitute a major transaction of the Company, which may be subject to the reporting, announcement and shareholders' approval requirements under Chapter 14 of the Listing Rules. The final transaction classification and compliance requirements will be determined based on the final consideration of the Disposal and the number of Consideration Shares to be issued.

As of the date of this announcement, Mr. Chen Xueli is the controlling shareholder and ultimate beneficial owner of the Company, and he directly and indirectly (through the Company and other controlled entities) controls Weigao Blood Purification. Weihai Shengxi is deemed to be a company controlled by Mr. Chen Xueli. As such, Weigao Blood Purification and Weihai Shengxi are associates of Mr. Chen Xueli and therefore connected persons of the Company. The Transaction will constitute a connected transaction of the Company, which is subject to the reporting, announcement and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

MATTERS TO BE SUPPLEMENTED

As of the date of this announcement, the valuation of the Subject Assets is yet to be completed. After the completion of the valuation, the final consideration for the transfer of the Subject Assets and the number of Consideration Shares to be issued will be agreed and confirmed by way of supplemental agreement, and the Company will hold a separate board meeting to review and approve the supplemental agreement.

The Company will comply with the applicable provisions of Chapter 14 and Chapter 14A of the Listing Rules and issue further announcement(s) regarding (among others) the valuation of the Subject Assets, the final consideration, the number of Consideration Shares to be issued, appointment of independent financial adviser and any other arrangements in due course.

As the Transaction is subject to the fulfillment and/or waiver of relevant conditions precedent and may not proceed, shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

Reference is made to the announcement of the Company dated 17 October 2025 in relation to the Company, Weihai Shengxi, Weihai Ruiming and Weigao Blood Purification entering into a non-legal binding letter of intent in relation to the Transaction.

The Board hereby announces that on 31 October 2025 (after trading hours), the Company, Weihai Shengxi, Weihai Ruiming, and Weigao Blood Purification entered into the conditional Sale and Purchase Agreement, pursuant to which Weigao Blood Purification will acquire 100% equity interest in WEGO Prefills, a non-wholly-owned subsidiary of the Company; and as the consideration, Weigao Blood Purification will issue a corresponding number of Consideration Shares to each of the WEGO Prefills Shareholders.

Principal Terms of the Sale and Purchase Agreement

The principal terms of the Sale and Purchase Agreement are set out below:

Date of Agreement and Conditions Precedent

31 October 2025

The Sale and Purchase Agreement shall be concluded after being executed and sealed by all parties hereto and shall become effective upon the fulfillment or satisfaction of the conditions precedent stipulated therein, including but not limited to the approvals of the Transaction by the boards and general meetings of Weigao Blood Purification and the Company, the approvals of the respective competent decision-making bodies of the other Vendors, and the approval of the competent regulatory authorities (including but not limited to the CSRC, the SSE and the Stock Exchange) in respect of the Transaction and/or the issuance of the Consideration Shares (as the case may be).

Parties

- 1) The Company, Weihai Shengxi and Weihai Ruiming (as the Vendors); and
- 2) Weigao Blood Purification (as the buyer)

Subject Assets and Consideration

Weigao Blood Purification intends to acquire 100% equity interest in WEGO Prefills from the Vendors by the issuance of A shares Consideration Shares. The Company, Weihai Shengxi and Weihai Ruiming shall dispose of approximately 94.0706%, 4.0215% and 1.9078% of the equity interest in WEGO Prefills, respectively.

The transfer consideration shall be determined through the negotiation among the parties with reference to the appraisal value of the Subject Assets as set out in the valuation report issued by an independent third-party asset appraisal institution, and a supplemental agreement will be executed by the parties to specify the details upon finalization.

Proposal for the Transaction

The specific proposal for the Transaction is as follows:

1) Class, Nominal Value and Place of Listing of the Consideration Shares

The Consideration Shares shall be domestic listed RMB ordinary shares (A shares) of Weigao Blood Purification, with a nominal value of RMB1.00 per share, and the place of listing shall be the SSE.

2) Method of Issuance and Target Subscribers

The method for issuance shall be issuing shares to a specific target subscriber, who will be the Vendors.

3) Pricing Benchmark Date and Issue Price

a) Pricing Benchmark Date and Issue Price

The Pricing Benchmark Date for the Transaction shall be the announcement date of the resolutions passed at the first session of the Board of Weigao Blood Purification in which the proposals related to the Transaction were considered (i.e. 1 November 2025).

The Issue Price shall not be less than 80% of the average trading price of the Shares of Weigao Blood Purification in the 20 Trading Days preceding to the Pricing Benchmark Date. As agreed among the parties, the Issue Price will be RMB31.29 per Consideration Share.

- b) During the period between the Pricing Benchmark Date for the Transaction and the completion date of the issuance, if there are any ex-rights or ex-dividend events of Weigao Blood Purification, such as distribution of dividends, issue of bonus shares, share allotment or capital reserve capitalization, the Issue Price of the Consideration Shares will be adjusted according to the following formula:

In the event of bonus issue or capital reserve capitalization: $P1 = P0 / (1 + n)$;

In the event of share allotment: $P1 = (P0 + A \times k) / (1 + k)$;

In the event of the above two items implemented simultaneously:
 $P1 = (P0 + A \times k) / (1 + n + k)$;

In the event of distribution of cash dividends: $P1 = P0 - D$;

In the event that the above three items are implemented simultaneously:
 $P1 = (P0 - D + A \times k) / (1 + n + k)$.

Where: P0 is the Issue Price before adjustment; n is the rate of bonus issue or rate of capital reserve capitalization; k is the rate of shares to be allotted; A is the share price to be allotted; D is the amount of cash dividends per share; and P1 is the adjusted Issue Price.

4) Number of Shares to be Issued

The number of Consideration Shares to be issued equals the consideration for the Subject Assets divided by the Issue Price of the Consideration Shares. The final number of Consideration Shares to be issued shall be subject to approval by the shareholders' meeting of Weigao Blood Purification, review by the SSE, and registration by the CSRC. In the event that the Issue Price of the Consideration Shares is adjusted pursuant to the events stipulated in the Sale and Purchase Agreement as mentioned above, the number of Consideration Shares to be issued shall be adjusted accordingly.

5) Lock-up Period

- a) The Vendors shall not transfer the Consideration Shares within thirty-six months following the completion of the Transaction. The lock-up period for the Consideration Shares shall automatically be extended for six months on the basis of the aforementioned lock-up period if the closing prices of the shares of Weigao Blood Purification is lower than the Issue Price for 20 consecutive trading days within six months after the completion of the Transaction or if the closing price of which at the end of the six months is lower than the Issue Price. For any shares of Weigao Blood Purification that have already been held by the Company prior to the Transaction, they shall not be transferred in any manner within 18 months after the completion of the Transaction. However, transfer of shares as permitted by applicable laws shall not be restricted.
- b) After the completion of the Transaction, any additional Consideration Shares received by the Vendors as a result of distribution of dividends, issue of bonus shares, capital reserve capitalization or share allotment or other actions of Weigao Blood Purification shall also be subject to the aforementioned lock-up period restrictions.
- c) In the event that the lock-up period for the shares subscribed by the Vendors is inconsistent with the latest regulatory requirements of the securities regulatory authorities, the Vendors agree to make corresponding adjustments in accordance with the latest requirements and regulatory advice of the securities regulatory authorities.
- d) Upon the expiry of the aforementioned lock-up period, the transfer and trading of the shares of Weigao Blood Purification by the Vendors shall be conducted in accordance with the then effective laws, regulations, and the rules of the SSE.

6) Arrangement of Accumulated Undistributed Profits

Upon the completion of the Transaction, all the existing and new shareholders of Weigao Blood Purification upon the completion of the Transaction will be entitled to the accumulated undistributed profits of Weigao Blood Purification as of the completion date of the issuance in proportion to their respective shareholdings.

7) Attribution of Profits or Losses of WEGO Prefills during the Transition Period

Regarding the profit or loss arrangements during the transition period of the Transaction, the relevant parties will execute a supplemental agreement to determine such arrangements after the completion of the asset audit and valuation of WEGO Prefills, and will disclose the same in due course.

Completion

Within 30 working days upon the fulfillment or satisfaction of all the conditions precedent to the effectiveness of the Sale and Purchase Agreement, the Vendors shall cooperate with Weigao Blood Purification and WEGO Prefills to complete the industrial and commercial registration procedures of the Disposal, following which Weigao Blood Purification shall complete the issuance and registration procedures of the Consideration Shares as soon as practicable.

Upon the completion of the Transaction, WEGO Prefills will become a wholly-owned subsidiary of Weigao Blood Purification, while Weigao Blood Purification may become a non-wholly-owned subsidiary of the Company. The accounts of WEGO Prefills, Weigao Blood Purification and their subsidiaries may be consolidated into the financial statements of the Company.

REASONS FOR AND BENEFITS OF THE TRANSACTION

The pharmaceutical packaging materials sector, such as pre-filled and automatic safety drug delivery systems, shows a strong growth momentum, with WEGO Prefills holding a leading market position in these related business areas

WEGO Prefills focuses on the research and development, production, and sales of pharmaceutical packaging materials such as pre-filled drug delivery systems and automatic safety drug delivery systems. According to the 14th Five-Year Plan for Pharmaceutical Industry Development (「十四五」醫藥工業發展規劃) promulgated by the Ministry of Industry and Information Technology of the PRC, the National Development and Reform Commission and other ministries, the State will enhance the quality of products in key areas, improve the standard system and quality regulations for pharmaceutical excipients, packaging materials and others. According to the Industrial Structure Adjustment Guidance Catalogue (2024 Edition) (產業結構調整指導目錄(2024年本)) promulgated by the National Development and Reform Commission, it is encouraged to develop supporting industries for biopharmaceuticals, including the development and production of new packaging systems, drug delivery devices and others. The pre-filled drug delivery systems and automatic safety drug delivery systems are mainly applied in the biopharmaceutical sectors. In recent years, with the robust development of downstream industries such as biopharmaceuticals and vaccines, the market demand for pharmaceutical packaging materials such as pre-filled drug delivery systems and automatic safety drug delivery systems has grown rapidly. As one of the earliest domestic manufacturers to overcome industry barriers, WEGO Prefills has seized a prominent position in the industry. According to the explanation of China National Pharmaceutical Packaging Association, during the period from 2022 to 2024, the market share of WEGO Prefills's pre-filled products in China's domestic market had exceeded 50%, ranking the top in the domestic industry and among the top five companies in international market in terms of sales volume.

The market prospects for upstream biopharmaceutical products such as filters are promising, and the localization process in the PRC is thriving and far from reaching its peak. The synergy between WEGO Prefills and Weigao Blood Purification in technology, products and sales channels has laid a solid foundation for the development of related businesses

According to data released by Frost & Sullivan, the market size of biopharmaceuticals in the PRC increased from RMB262.2 billion in 2018 to RMB534.8 billion in 2024, with a compound annual growth rate of 12.61%. With the continuous investments in innovation as well as research and development, the advancement of preparation processes for biopharmaceuticals, as well as the strong support of relevant industrial policies, the market size of biopharmaceuticals in the PRC will maintain its trend of rapid growth. It is expected that by 2028 and 2032, the market size of biopharmaceuticals in the PRC will grow to RMB830.8 billion and RMB1,126.8 billion, respectively, with compound annual growth rates of 11.64% and 7.92%.

With the rapid development of the biopharmaceutical industry, in addition to the rapid growth in demand for pharmaceutical packaging materials such as pre-filled and automatic safety drug delivery systems required for finished drugs, the market demand for upstream biopharmaceutical products such as filters needed by biopharmaceutical manufacturers for product research and development and production has also increased, presenting a promising market prospect.

Weigao Blood Purification possesses a biomedical membrane technology platform with multi-disciplinary R&D and commercialization potential. Based on this proprietary platform, it has completed the technological research and development and trial production of biopharmaceutical filter products. WEGO Prefills has been deeply engaged in the field of pharmaceutical packaging materials for years and has a rich customer base in the biopharmaceutical sector. In terms of technology, products and sales channels, the synergy between the two parties has laid a solid foundation for the development of upstream biopharmaceutical businesses such as filters.

Seizing the development opportunities in the biopharmaceutical industry, fully leveraging the biomedical membrane-related core technologies of Weigao Blood Purification and the rich customer resources of WEGO Prefills in the biopharmaceutical industry, and jointly exploring the upstream business market of biopharmaceuticals with a focus on biopharmaceutical filters

After the completion of the Transaction, Weigao Blood Purification can integrate the technological experience and product offering of WEGO Prefills and expand its product lines into the pharmaceutical packaging materials sector. Simultaneously, by fully leveraging the technological advantages of Weigao Blood Purification in hollow fiber filtration and the rich customer resources of WEGO Prefills in the biopharmaceutical field, both parties can mutually empower each other in terms of product technology reserves and sales channels in the biopharmaceutical filter business, and jointly explore the upstream business market of biopharmaceuticals with a focus on biopharmaceutical filters.

Integrating high-quality assets to further enhance the profitability and investment value of the two listed companies is in the interests of the Company and all the shareholders

The Group currently holds approximately 23.53% direct equity interest in Weigao Blood Purification. The Company anticipates further increasing its shareholding in Weigao Blood Purification through the Transaction, while leveraging the full synergy between Weigao Blood Purification and WEGO Prefills, the overall business scope of the Group will further expand, and the Group's overall profitability is expected to be further enhanced. Therefore, the Board considers that, if the Transaction is completed, WEGO Prefills and Weigao Blood Purification will generate business synergies, and the overall business scope of the Group will be further expanded.

INFORMATION ON WEGO PREFILLS

WEGO Prefills focuses on the research and development, production, and sales of pharmaceutical packaging materials such as pre-filled drug delivery systems and automatic safety drug delivery systems. It is committed to providing one-stop drug delivery solutions for global biopharmaceutical companies. As of the date of this announcement, the registered capital of WEGO Prefills is approximately RMB106.3 million. The Company, Weihai Shengxi, and Weihai Ruiming hold 94.0706%, 4.0215% and 1.9078% equity interests in WEGO Prefills respectively. WEGO Prefills wholly owns two subsidiaries, namely Shandong Weigao Pharmaceutical Packaging Products Co., Ltd.* (山東威高醫藥包裝製品有限公司) and Weihai Weigao Jiesheng Medical Devices Co., Ltd.* (威海威高潔盛醫療器材有限公司).

According to the consolidated financial statements (unaudited) prepared by WEGO Prefills in accordance with the China Accounting Standards for Business Enterprises, as at 30 June 2025, total assets of WEGO Prefills amounted to approximately RMB3,425.34 million, total liabilities amounted to approximately RMB730.01 million, and owner's equity amounted to approximately RMB2,695.34 million. The profit before and after tax of WEGO Prefills for the two years ended 31 December 2023 and 2024 and for the six months ended 30 June 2025 are as follows:

	For the year ended 31 December 2023 <i>(In approximately RMB million)</i> (Unaudited)	For the year ended 31 December 2024 <i>(In approximately RMB million)</i> (Unaudited)	For the six months ended 30 June 2025 <i>(In approximately RMB million)</i> (Unaudited)
Profit before tax	560.11	680.98	380.67
Profit after tax	489.59	584.75	327.38

INFORMATION ON WEIGAO BLOOD PURIFICATION

Weigao Blood Purification is a joint stock company established on 27 December 2004 in accordance with the laws of the PRC. It is primarily engaged in the businesses of research and development, production, and sales of medical products for blood purification. Its main products include hemodialyzers, hemodialysis tubing sets, hemodialysis machines, and peritoneal dialysis solutions, covering both hemodialysis and peritoneal dialysis fields, supplemented by the sales of supporting dialysis products. It is one of the domestic manufacturers of medical products for blood purification with the most comprehensive product lines. Its shares are listed on the SSE (stock code: 603014.SH). As at the date of this announcement, Weigao Blood Purification is controlled by Weigao Holding, a controlling shareholder of the Company. The Company also directly holds 23.53% of the shares.

According to the financial statements prepared by Weigao Blood Purification in accordance with the China Accounting Standards for Business Enterprises, as at 30 September 2025, the total assets of Weigao Blood Purification amounted to approximately RMB8,468.25 million, total liabilities amounted to approximately RMB1,486.19 million, and owner's equity amounted to approximately RMB6,982.07 million, all being unaudited. The profit before and after tax of Weigao Blood Purification for the two years ended 31 December 2023 and 2024 and for the nine months ended 30 September 2025 are as follows:

	For the year ended 31 December 2023 <i>(In approximately RMB million)</i> (Audited)	For the year ended 31 December 2024 <i>(In approximately RMB million)</i> (Audited)	For the nine months ended 30 September 2025 <i>(In approximately RMB million)</i> (Unaudited)
Profit before tax	523.81	545.68	406.41
Profit after tax	442.07	449.37	340.78

INFORMATION ON VENDORS

The Company is a total solution provider in the medical device sector in China and principally engaged in the research and development, production and sale of single-use medical devices. The Group has a wide range of products, which includes: infusion sets, syringes, needles, orthopaedic products, interventional products, pharma packaging products, blood management products and is also engaged in financial leasing and factoring businesses in China.

Weihai Ruiming is a limited liability partnership established on 21 August 2025 in accordance with the laws of the PRC, and is an employee shareholding platform for WEGO Prefills. Its managing partner is Weihai Weigao Qiming Enterprise Management Consulting Service Co., Ltd.* (威海威高啟明企業管理諮詢服務有限公司), a subsidiary of the Company. As of the date of this announcement, Weihai Weigao Qiming Enterprise Management Consulting Service Co., Ltd. and 34 employees of WEGO Prefills hold 0.99% and 99.01% of the limited partnership shares of Weihai Ruiming, respectively.

Weihai Shengxi is a limited liability partnership established on 27 August 2018 in accordance with the laws of the PRC, which is primarily engaged in investment holding operations. As of the date of this announcement, the managing partner of Weihai Shengxi is Weihai Weigao Finance Holding Company Limited* (威海威高金融控股有限公司), which is 100% held by Mr. Chen Xueli through Weigao Holding and Weihai Weigao International. In addition, Weihai Weigao Finance Holding Company Limited and Mr. Chen Lin, a non-executive Director, hold 10% and 90% of the limited partnership shares of Weihai Shengxi, respectively.

IMPLICATIONS UNDER THE LISTING RULES

Based on the information available so far, the Company estimated that the respective highest applicable percentage ratios for the Disposal and the Acquisition may exceed 25% but below 75%/100% (as the case may be), and therefore may constitute a major transaction of the Company, which may be subject to the reporting, announcement and shareholders' approval requirements under Chapter 14 of the Listing Rules. The final transaction classification and compliance requirements will be determined based on the final consideration of the Disposal and the number of Consideration Shares to be issued.

As of the date of this announcement, Mr. Chen Xueli is the controlling shareholder and ultimate beneficial owner of the Company, and he directly and indirectly (through the Company and other controlled entities) controls Weigao Blood Purification. Weihai Shengxi is deemed to be a company controlled by Mr. Chen Xueli. As such, Weigao Blood Purification and Weihai Shengxi are associates of Mr. Chen Xueli and therefore connected persons of the Company. The Transaction constitutes a connected transaction of the Company, which is subject to the reporting, announcement and independent shareholders' approval requirements under Chapter 14A of the Listing Rules.

Mr. Long Jing, Mr. Cong Rinan, Mr. Chen Lin and Mr. Tang Zhengpeng are concurrently serving as directors of Weigao Holding, and Mr. Wang Daoming is the director and general manager of WEGO Prefills and a limited partner of Weihai Ruiming. They have abstained from voting on the relevant resolutions on the Transaction at the board meeting of the Company. Save as disclosed above, no Director has a material interest in the Transaction or abstained from voting on the relevant board resolutions approving the Transaction. The Directors (excluding the independent non-executive Directors, whose views will be set out in the letter from the Independent Board Committee to be sent to shareholders) consider that the terms of the Sale and Purchase Agreement are on normal commercial terms, fair and reasonable, and are in the interests of the Company and its Shareholders as a whole.

MATTERS TO BE SUPPLEMENTED

As at the date of this announcement, the valuation of the Subject Assets is yet to be completed. After the completion of the valuation, the final consideration for the transfer of the Subject Assets and the number of Consideration Shares to be issued will be agreed and confirmed by way of supplemental agreement and the Company will hold a separate board meeting to review and approve the supplemental agreement.

The Company will comply with the applicable requirement under Chapters 14 and 14A of the Listing Rules and issue further announcement(s) regarding (among others) the valuation of the Subject Assets, the final consideration, the number of Consideration Shares to be issued, appointment of independent financial adviser and any other arrangements in due course.

As the Transaction is subject to the fulfillment and/or waiver of relevant preconditions and may or may not proceed, shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions shall have the following meaning:

“Acquisition”	the transaction whereby the Company and Weihai Ruiming shall receive the Consideration Shares pursuant to the Sale and Purchase Agreement in connection with the Disposal
“associate(s)”	has the meaning ascribed thereto under the Listing Rules

“Board”	the board of Directors of the Company
“Company”	Shandong Weigao Group Medical Polymer Company Limited (山東威高集團醫用高分子製品股份有限公司), a joint stock limited company established in the PRC, the H shares of which are listed on the Main Board of the Stock Exchange
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Consideration Shares”	Weigao Blood Purification issues new ordinary shares with a nominal value of RMB1.00 each to WEGO Prefills Shareholders pursuant to the Sale and Purchase Agreement, as the consideration to acquire the equity interests in WEGO Prefills
“controlling shareholder”	has the meaning ascribed thereto under the Listing Rules
“CSRC”	the China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)”	the director(s) of the Company
“Disposal”	the Company and Weihai Ruiming sold a total of 95.9784% equity interest in WEGO Prefills to Weigao Blood Purification pursuant to the Sale and Purchase Agreement
“Group”	the Company and its subsidiaries
“Completion Date of Issuance”	the date on which the Consideration Shares are registered in the Company’s share account opened with China Securities Depository and Clearing Corporation Limited (中國證券登記結算有限責任公司)

“Issue Price”	the issue price of the Consideration Shares, being RMB31.29 per Consideration Share (subject to adjustment upon the events specified in the Sale and Purchase Agreement)
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“PRC”	the People’s Republic of China, excluding, for the purposes of this announcement only, excluding Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan
“PN15”	Practice Note 15 of the Listing Rules
“Pricing Benchmark Date”	the pricing benchmark date for the issuance of the Consideration Shares, being 1 November 2025
“Sale and Purchase Agreement”	the share issue and sale and purchase of assets agreement dated 31 October 2025 entered into between WEGO Prefills Shareholders and Weigao Blood Purification in relation to the Transaction
“SSE”	the Shanghai Stock Exchange
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Subject Assets”	the 100% equity interest in WEGO Prefills
“Transaction”	the transaction whereby Weigao Blood Purification acquires the 100% equity interest in WEGO Prefills from WEGO Prefills Shareholders by the way of issuance of Consideration Shares

“Weigao Holding”	Weigao Holding Co., Ltd.* (威高集團有限公司), a company established under the laws of the PRC with limited liability, which holds 46.17% of the shares of the Company in total. It is a controlling shareholder and a connected person of the Company as at the date of this announcement
“Weigao Blood Purification”	Shandong Weigao Blood Purification Products Co., Ltd.* (山東威高血液淨化製品股份有限公司), a company established in the PRC whose shares are listed on the SSE (stock code: 603014.SH). It is a connected person of the Company
“WEGO Prefills”	WEGO Prefills Pharmaceutical Packaging Co., Ltd.* (山東威高普瑞醫藥包裝有限公司), a company established under the laws of the PRC with limited liability. It is a non-wholly owned subsidiary of the Company
“WEGO Prefills Shareholders” or “Vendors”	any or all existing shareholders of WEGO Prefills, namely the Company, Weihai Shengxi and Weihai Ruiming
“Weihai Shengxi”	Weihai Shengxi Enterprise Management Consulting Center (Limited Partnership)* (威海盛熙企業管理諮詢中心(有限合夥)), a limited liability partnership established under the laws of the PRC. It is a connected person of the Company
“Weihai Ruiming”	Weihai Ruiming Enterprise Management Consulting Partnership (Limited Partnership)* (威海瑞明企業管理諮詢合夥企業(有限合夥)), a limited liability partnership established under the laws of the PRC

“Weihai Weigao
International”

Weihai Weigao International Medical Investment Holding Co., Ltd.* (威海威高國際醫療投資控股有限公司), a company established under the laws of the PRC with limited liability. It controls the Company through Weigao Holding as at the date of this announcement. It is a controlling shareholder and a connected person of the Company

As the Transaction is subject to the satisfaction and/or waiver of the relevant conditions precedent and may or may not proceed, Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Long Jing
Chairman

31 October 2025

Weihai, Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive Director*)

Mr. Lu Junqiang (*Executive Director*)

Mr. Wang Daoming (*Executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Li Guohui (*Independent Non-executive Director*)

Mrs. Meng Hong (*Independent Non-executive Director*)

Mr. Li Qiang (*Independent Non-executive Director*)

Mr. Sun Heng (*Independent Non-executive Director*)

* *For identification purposes only*